# S1 Fracture / Fragility Semantics — P6B R1 programme reconciliation

> **STATUS:** INDEPENDENT DELTA+CUMULATIVE P6B PASS ACCEPTED / RELEASE HOLD.
> **Date:** 2026-09-30.
> **Programme role:** coordinator reconciliation only.
> **PR:** #123 — OPEN / DRAFT / NOT MERGED.
> **Exact independently reviewed target:** `ba2f8635372f85cd94409fa66e08c3d8b428bcba`.
> **Blocked predecessor:** `f4fe36bcfbd0ca475768844387536ec71e2fd38d`.
> **Original base main:** `2ae9f01ded14bd2106ee09f47acb3fea4d72bc4b`.
> **Fresh main at reconciliation:** `cbe8d10891d21af2c48da9fabe8bd475f53e584a`.
> **Root writer lock:** unchanged — OST-CAPTURE / PR-1.

## Accepted independent result

The fresh separate independent R1 delta+cumulative P6B review verified exact target identity with no drift and returned PASS with no material residual.

Accepted closures:

- raw noncanonical `low_trauma` survives ordinary no-edit load/render/save unchanged;
- explicit clinician edit persists canonical replacement;
- semantic normalization remains stable and unknown/unrecognised values remain fail-closed;
- prior D1–D6 closures remain preserved;
- generic fracture, VFA, fracture-on-treatment/R07, R05/R06/R08 boundaries, denosumab and therapy-milestone behavior remain preserved;
- no schema/database/persistence/PR-1/Product-Constitution/LifeCourse scope expansion occurred.

Independent exact-head CI evidence was adequate and green.

## Programme disposition

```text
S1 PRE-CODE                         COMPLETE
S1 IMPLEMENTATION                   COMPLETE
S1 RESIDUAL R1 CORRECTION           COMPLETE
S1 DELTA+CUMULATIVE P6B              PASS / ACCEPTED
MATERIAL RESIDUAL                    NONE
MERGE                                NOT YET AUTHORIZED
DEPLOY                               NOT AUTHORIZED
SMOKE                                NOT AUTHORIZED
ROOT WRITER TRANSFER                 NO
```

No review-of-review is opened.

## Fresh-main release context

Fresh `main` has advanced beyond the original S1 base.

Comparison of original base → current main shows current-main changes in Calendar/Cockpit/Learning/Surgery-Queue surfaces and no direct modification of the bounded S1 product/test paths.

This supports a bounded release reconciliation rather than reopening clinical implementation review, but it does not itself authorize merge.

## Exact next action

1. preserve the independently reviewed substantive identity `ba2f863...`;
2. verify the coordinator-only documentation checkpoint on PR #123 and its CI;
3. perform bounded release reconciliation against fresh current main;
4. wait for explicit Product Owner merge authority;
5. after any authorized merge, checkpoint auto-deploy and production smoke separately.

A new independent review is required only if runtime/test content changes materially or fresh-main reconciliation exposes a relevant interaction not covered by the accepted P6B evidence.
